The global extracellular matrix market accounted to US$ 24.30 Mn in 2018 and is expected to grow at a CAGR of 8.2% during the forecast period 2019 – 2027
The Extracellular matrix market is an emerging in nature with consisting of the good and countable number of players, having considerable revenue in the market. Most of the companies operating in the global extracellular matrix market are offers extracellular matrix for wound care and injuries caused due to various medical conditions such as cardiovascular diseases, cancer, and others.
The most notable Extracellular matrix market participants are Admedus, Coloplast Group, Merck KGaA, Smith & Nephew, MTF Biologics, Lattice Biologics Ltd., COOK BIOTECH, INC., Medtronic, Aziyo Biologics, Inc., and DSM Biomedical among the others have occupied a considerable share of the market owing to their product offerings to the companies.
Market leaders are involved in organic and inorganic growth strategies in the extracellular matrix market. For instance, the companies have maximized their growth with several organic strategies to enhance the market value and position in the market. The organic developments in the market were maximum among the development in the extracellular matrix.
The Extracellular matrix market has experienced several organic strategies such as product launch, product approval and expansion activities that has resulted positively for the growth of the market. The companies have also conducted inorganic strategies such as agreements, partnership and acquisitions that has enhance the product portfolio.
Below is the list of the inorganic and organic strategies done by the players operating in the Extracellular Matrix Market:
|March, 2019||MTF Biologics launched CartiMax Viable Cartilage, for easily filling the lesions in the knee, foot and ankle. The launch demonstrates stable viability post-cryopreservation and provides the clinical benefits of, viable cartilage matrix with live cells.||North America|
|April, 2019||Smith & Nephew plc completed the acquisition of Osiris Therapeutics, Inc. Osiris provides regenerative medicine products which include skin, bone graft and articular cartilage substitutes.||North America|
|July, 2018||Merck expanded its Gillingham, UK distribution centre. The new facility serves as the primary distribution centre for the UK. The aim of the distribution centre is to expand Life Science products to support business growth.||Europe|
|June, 2017||Lattice Biologics Ltd. relocated its processing facilities to Belgrade, Montana. The relocation aims to focus on higher margin products and to develop processing automation needed to meet current orders.||North America|
|November, 2016||Coloplast acquired Comfort Medical, a US supplier of the catheters and ostomy products. The acquisition enhanced the Coloplast’s mission of enhancing the products and services to the US market.||North America|
|September, 2015||Cook Biotech received FDA approval for the Biodesign Otologic Repair Graft. The graft is a multi-layer biomaterial derived from porcine small intestinal submucosa that aids in the natural healing process in various otologic procedures||North America|